Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533553 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Areteia Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT06533553 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that is active but no longer recruiting, run by Areteia Therapeutics. The registered enrollment target is 30 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06533553, a Phase 2 study of Chronic Obstructive Pulmonary Disease, is active but no longer recruiting, sponsored by Areteia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Conditions Studied
Interventions
- DRUG Dexpramipexole Dihydrochloride
Study Locations (20)
California
- Research Site US-10001-008 - Newport Beach
- Research Site US-10001-022 - Northridge
- Research Site US-10001-016 - Westminster
North Carolina
- Research US-10001-010 - Charlotte
- Research Site US-10001-025 - Charlotte
- Research Site US-10001-007 - Gastonia
Missouri
- Research Site US-10001-005 - Saint Charles
- Research Site US-10001-001 - St Louis
Pennsylvania
- Research Site US-10001-002 - DuBois
- Research Site US-10001-013 - Philadelphia
Arkansas
- Research Site US-10001-017 - Conway
Florida
- Research Site US-10001-030 - Orlando
Illinois
- Research Site 10001-032 - Champaign
Indiana
- Research Site US-10001-021 - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06533553
The ClinicalTrials.gov registry entry for NCT06533553 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The listed sponsor is Areteia Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Dexpramipexole Dihydrochloride is the first listed.
NCT06533553 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, North Carolina, Missouri.
Frequently Asked Questions
What is clinical trial NCT06533553 about?
NCT06533553 is a clinical study titled "A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD". This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
What is the current status of trial NCT06533553?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-07-09. Estimated completion is 2025-12.
What conditions does trial NCT06533553 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06533553?
The interventions under investigation include: Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT06533553?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533553 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.